Eiger BioPharmaceuticals, Inc. Quarterly Operating Lease, Payments in USD from Q1 2019 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
Eiger BioPharmaceuticals, Inc. quarterly/annual Operating Lease, Payments history and growth rate from Q1 2019 to Q1 2023.
  • Eiger BioPharmaceuticals, Inc. Operating Lease, Payments for the quarter ending March 31, 2023 was $200K, unchanged year-over-year.
  • Eiger BioPharmaceuticals, Inc. annual Operating Lease, Payments for 2022 was $700K, a 16.7% increase from 2021.
  • Eiger BioPharmaceuticals, Inc. annual Operating Lease, Payments for 2021 was $600K, a 14.3% decline from 2020.
  • Eiger BioPharmaceuticals, Inc. annual Operating Lease, Payments for 2020 was $700K, a 16.7% increase from 2019.
Operating Lease, Payments, Quarterly (USD)
Operating Lease, Payments, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 $200K $0 0% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q1 2022 $200K $0 0% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q1 2021 $200K $0 0% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q1 2020 $200K +$100K +100% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q1 2019 $100K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.